{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Campath-1h&page=2", "query": { "intervention": "Campath-1h", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 279, "total_pages": 28, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Campath-1h&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Campath-1h&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T00:04:33.034Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01465334", "title": "Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "CLL", "SLL" ], "interventions": [ { "name": "Ofatumumab", "type": "DRUG" }, { "name": "High-Dose Methylprednisolone", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2011-12", "completion_date": "2017-01", "has_results": true, "last_update_posted_date": "2023-08-29", "last_synced_at": "2026-10-02T00:04:33.034Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01465334" }, { "nct_id": "NCT01729494", "title": "Belatacept Early Steroid Withdrawal Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Renal Transplantation" ], "interventions": [ { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "rabbit antithymocyte globulin", "type": "DRUG" }, { "name": "Belatacept", "type": "DRUG" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" }, { "name": "early cessation of steroids", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 316, "start_date": "2012-09", "completion_date": "2019-12", "has_results": true, "last_update_posted_date": "2026-07-24", "last_synced_at": "2026-10-02T00:04:33.034Z", "location_count": 8, "location_summary": "San Francisco, California • Denver, Colorado • Tampa, Florida + 4 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01729494" }, { "nct_id": "NCT00684255", "title": "Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Systemic Lupus Erythematosus", "Systemic Sclerosis" ], "interventions": [ { "name": "Reduced Intensity Allogeneic Transplant", "type": "PROCEDURE" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Campath", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "New York Medical College", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "7 Years to 50 Years" }, "enrollment_count": 1, "start_date": "2007-08", "completion_date": "2008-07", "has_results": true, "last_update_posted_date": "2014-04-01", "last_synced_at": "2026-10-02T00:04:33.034Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00684255" }, { "nct_id": "NCT03653338", "title": "T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Sickle Cell Anemia", "Beta-thalassemia Major", "Diamond-blackfan Anemia" ], "interventions": [ { "name": "CD3/CD19 depleted leukocytes", "type": "BIOLOGICAL" }, { "name": "CD45RA depleted leukocytes", "type": "BIOLOGICAL" }, { "name": "Hydroxyurea", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Paul Szabolcs", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "5 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "5 Years to 40 Years" }, "enrollment_count": 5, "start_date": "2018-08-02", "completion_date": "2028-08-01", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-10-02T00:04:33.034Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03653338" }, { "nct_id": "NCT06959771", "title": "Base Editing Hematopoietic Stem Cell and T Cell Gene Therapy for CD40L-HyperIgM Syndrome: Single Patient Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "CD40L-HyperIgM Syndrome" ], "interventions": [ { "name": "Base-edited hematopoietic stem and progenitor cells", "type": "BIOLOGICAL" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Sirolimus", "type": "DRUG" }, { "name": "Palifermin", "type": "DRUG" }, { "name": "Busulfan", "type": "DRUG" }, { "name": "Base-edited T lymphocyte cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "37 Years", "maximum_age": "120 Years", "sex": "MALE", "summary": "37 Years to 120 Years · Male only" }, "enrollment_count": 1, "start_date": "2025-07-16", "completion_date": "2027-10-28", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-02T00:04:33.034Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06959771" }, { "nct_id": "NCT03630211", "title": "Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Sclerosis", "Diffuse Sclerosis Systemic", "Interstitial Lung Disease", "Pulmonary Hypertension" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Thiotepa", "type": "DRUG" }, { "name": "GM-CSF", "type": "DRUG" }, { "name": "Intravenous immunoglobulin", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Anti Thymocyte Globulin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Paul Szabolcs", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "8 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "8 Years to 60 Years" }, "enrollment_count": 8, "start_date": "2018-07-31", "completion_date": "2028-08-01", "has_results": false, "last_update_posted_date": "2026-08-14", "last_synced_at": "2026-10-02T00:04:33.034Z", "location_count": 2, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03630211" }, { "nct_id": "NCT00301834", "title": "Alemtuzumab, Fludarabine, and Busulfan Followed By Donor Stem Cell Transplant in Treating Young Patients With Hematologic Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Congenital Amegakaryocytic Thrombocytopenia", "Diamond-blackfan Anemia", "Leukemia", "Myelodysplastic Syndromes", "Severe Congenital Neutropenia" ], "interventions": [ { "name": "alemtuzumab", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 35, "start_date": "2005-01", "completion_date": "2011-09", "has_results": true, "last_update_posted_date": "2017-09-28", "last_synced_at": "2026-10-02T00:04:33.034Z", "location_count": 2, "location_summary": "San Francisco, California • Madison, Wisconsin", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00301834" }, { "nct_id": "NCT01191749", "title": "Alemtuzumab in Myelodysplastic Syndrome (MDS), Aplastic Anemia, and T-Cell Large Granular Lymphocytic Leukemia (T-GL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Alemtuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 7, "start_date": "2010-08", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2017-05-09", "last_synced_at": "2026-10-02T00:04:33.034Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01191749" }, { "nct_id": "NCT00177138", "title": "Use of Campath for Induction and Maintenance Therapy in Pancreas After Kidney Transplantation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Alemtuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 9, "start_date": "2004-07", "completion_date": "2006-11", "has_results": false, "last_update_posted_date": "2013-02-07", "last_synced_at": "2026-10-02T00:04:33.034Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00177138" }, { "nct_id": "NCT01256398", "title": "Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1" ], "interventions": [ { "name": "Alemtuzumab", "type": "BIOLOGICAL" }, { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Daunorubicin Hydrochloride", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Etoposide Phosphate", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Fludarabine Phosphate", "type": "DRUG" }, { "name": "In Vitro-Treated Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Leucovorin Calcium", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Mercaptopurine", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Tacrolimus", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2010-12-14", "completion_date": "2021-11-15", "has_results": true, "last_update_posted_date": "2023-04-04", "last_synced_at": "2026-10-02T00:04:33.034Z", "location_count": 101, "location_summary": "Palo Alto, California • Aurora, Colorado • Boulder, Colorado + 68 more", "locations": [ { "city": "Palo Alto", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Boulder", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01256398" } ] }